awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q43492386-23825C54-6807-4F90-91AF-38F7606B3D3F
Q43492386-23825C54-6807-4F90-91AF-38F7606B3D3F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43492386-23825C54-6807-4F90-91AF-38F7606B3D3F
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
P577
Q43492386-23825C54-6807-4F90-91AF-38F7606B3D3F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43492386-23825C54-6807-4F90-91AF-38F7606B3D3F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
459a8613dfc757ad17ff39054b608d4e5242fc82
P577
2013-05-18T00:00:00Z
http://www.w3.org/2001/XMLSchema#dateTime
P577
8014948999146aa8a8221f3d0f3773fd